RN1001(Avotermin) in Scar Improvement Following Breast Augmentation

Inclusion Criteria: * Female subjects between 18 and 60 years of age undergoing bilateral breast augmentation through an infra-mammary fold incision who have given written informed consent. * Weight between 50 and 150kg and a body mass index within the permitted range for their height using Quetelet's index-weight (kg)/height²(m). The permitted index is between 15-55. * Subjects of child bearing potential who are using method(s) of contraception acceptable to the Investigator and agree to do so from at least the screening visit until 1 month post surgery. * Subjects where the same implant position will be used for each breast; the implants can be placed in sub-mammary or sub-pectoral pockets. * Subjects where the same type and size of implant is to be used for each breast. * Subjects with, in the opinion of the Investigator, clinically acceptable results for the laboratory tests specified in the trial protocol . All laboratory tests must be performed within 28 days prior to Day 0. Exclusion Criteria: * Subjects with significant breast asymmetry where this may produce a different length or site of wound, or where there will be a different post-operative tension on the wound. * Subjects who on direct questioning and physical examination have a history or evidence of hypertrophic or keloid scarring. * Subjects who have had surgery in the area to be incised within one year of Day 0. * Subjects with a personal history of a bleeding disorder. * Subjects with any history of breas…